September 2018 Vol 11, No 6
Trends in Utilization, Spending, and Prices of Smoking-Cessation Medications in Medicaid Programs: 25 Years Empirical Data Analysis, 1991-2015
Part of this information was presented as a poster at the 2016 Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
The Importance and Benefits of Smoking-Cessation Therapy
Analysis of Real-World Dosing Patterns for the 3 FDA-Approved Medications in the Treatment of Fibromyalgia
Craig White, PhD, Winghan Jacqueline Kwong, PharmD, PhD, Hilary Armstrong, PhD, Michael Behling, Research Associate, Jeffrey Niemira, Senior Statistician, Kathy Lang, PhD
Preliminary results of this study were presented as a poster at the American Society of Health-System Pharmacists 2017 Summer Meetings and Exhibition.
Real-World Drug Prescribing and Utilization Studies Can Inform Optimized Patient Care and Insurance Coverage
Estimating the Real-World Cost of Diabetes Mellitus in the United States During an 8-Year Period Using 2 Cost Methodologies
Vincent J. Willey, PharmD, Sheldon Kong, PhD, Bingcao Wu, MS, Amit Raval, PhD, Todd Hobbs, MD, Andrea Windsheimer, PharmD, Gaurav Deshpande, MS, PhD, Ozgur Tunceli, PhD, Brian Sakurada, PharmD, Jonathan R. Bouchard, MS, RPh
Diabetes mellitus imposes a substantial clinical and economic burden on the US healthcare system. National estimates reported in 2017 indicate that 9.4% of the US population, or 30.3 million Americans, have diabetes; however, only 23.1 million have actually been diagnosed with the disease, which means that 7.2 million people (or 23.8% of those with diabetes) were undiagnosed.
Results 1 - 4 of 4